Here are the 10-K annual reports from Tivic Health Systems, Inc. (TIVC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TIVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TIVC filings page.
Tivic Health Systems, Inc. files its annual report outlining a major pivot from bioelectronic consumer devices to a late-stage biopharmaceutical strategy centered on Entolimod, a TLR5 agonist for Acute Radiation Syndrome and oncology-related complications such as neutropenia and thrombocytopenia. The company licensed Entolimod and next‑generation compound Entolasta in 2025 and created a CDMO subsidiary, Velocity Bioworks, supported by a financing package exceeding $90 million. Tivic reports net losses, an accumulated deficit and states there is substantial doubt about its ability to continue as a going concern, while also disclosing a material weakness in internal controls due to limited accounting staff. As of March 17, 2026, it had 2,877,926 shares outstanding and 52 employees, and is pursuing ARS and oncology opportunities, including potential U.S. government procurement for the Strategic National Stockpile.